Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17.5M

Overview

TriMed is a specialized orthopedic device company with a 30+ year history of developing fragment-specific fixation systems for complex periarticular fractures, primarily in the wrist, ankle, and other extremities. The company has carved out a niche by addressing limitations of traditional fixation methods, leveraging innovative designs like the Volar Bearing Plate and Sidewinder Plate. While smaller than many competitors, TriMed emphasizes superior customer service, surgeon education through seminars, and a strong clinical evidence base to maintain its position as a key player in the orthopedic trauma segment.

Orthopedic TraumaFracture Care

Technology Platform

Fragment-Specific Fixation (FSF) - A modular system of low-profile orthopedic implants designed for stable, multi-planar fixation of complex periarticular fractures, moving beyond traditional anatomic plates.

Funding History

2
Total raised:$17.5M
Series A$15M
Seed$2.5M

Opportunities

Expansion of its successful fragment-specific fixation platform into high-volume lower extremity markets like foot and ankle surgery represents a significant growth opportunity.
Additionally, the shift towards outpatient and value-based care favors implants that enable faster recovery, aligning perfectly with TriMed's design philosophy and creating demand for its specialized solutions.

Risk Factors

Intense competition from large, well-resourced orthopedic conglomerates poses a constant threat to market share.
The company also faces concentration risk, as its business is heavily reliant on the continued surgical preference for its specific fixation technique over alternatives like traditional plating, arthroplasty, or emerging disruptive technologies.

Competitive Landscape

TriMed competes in the orthopedic trauma device market, which is dominated by large public companies like Stryker, DePuy Synthes (Johnson & Johnson), Zimmer Biomet, and Smith & Nephew. Its competitive advantage is not scale, but deep specialization, innovative fragment-specific designs, and superior customer service for complex periarticular fractures, a niche where larger players may offer less tailored solutions.